secwatch.observer — SEC 8-K summary
======================================

Issuer:     STAAR SURGICAL CO (STAA)
CIK:        0000718937
Form:       8-K
Filed at:   2024-05-07T23:59:59+00:00
Accession:  0000950170-24-054454
Event type: earnings
Sentiment:  positive
Materiality: 0.80
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

STAAR Surgical Q1 net sales up 5% to $77.4M; net loss $0.07ps; raises FY24 EBITDA outlook
--------------------------------------------------------------------------------

- Net sales $77.4M (+5% YoY; +7% constant currency); ICL sales +9% on +2% units.
- Net loss $3.3M ($0.07 loss per share) vs net income $2.7M ($0.05) a year ago; Adjusted EBITDA $5.3M ($0.11) vs $10.0M ($0.20).
- U.S. sales $5M, up 15% YoY and 21% sequentially; record cash $252.1M.
- FY2024 net sales outlook reiterated at $335-$340M; Adjusted EBITDA guidance raised to ~$39M ($0.75 per share) from ~$36M.
- APAC sales +9% (China +10%); EMEA +11%; largest-ever U.S. practice commitment to EVO ICL announced.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/718937/000095017024054454/0000950170-24-054454-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/718937/000095017024054454/staa-20240507.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-054454

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer